icon- folder.gif   Conference Reports for NATAP  
  XVII International AIDS Conference
Mexico City
3-8 August 2008
Back grey_arrow_rt.gif
Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the Phase III DUET studies
  Reported by Jules Levin
IAC, Mexico City, Aug 3-8, 2008
Christine Katlama,1 Thomas Campbell,2 Mauro Schechter,3 Monika Peeters,4 Ceyhun Bicer,4 Rekha Sinha,4 Lorant Leopold,5 Goedele De Smedt4 1Hopital Pitie-Salpetriere, Paris, France; 2University of Colorado Denver, Denver, CO, USA;3Universidade Federal do Rio de Janeiro, Brazil; 4Tibotec BVBA, Mechelen, Belgium; 5Tibotec Inc., Yardley, PA, USA
Over 48 weeks, the incidence and severity of neuropsychiatric events of interest with ETR was comparable to placebo; events decreased over time
- headache and insomnia were the most commonly reported nervous system and psychiatric events, respectively, and occurred at similar instances in both treatment groups.
Incidences of grade 3 neuropsychiatric events of interest were low and similar between treatment groups.
No grade 4 neuropsychiatric events of interest were reported with ETR.
ETR was associated with low discontinuation rates and incidence of serious AEs.
Although psychiatric history was associated with an increased frequency of neuropsychiatric events of interest, incidences were comparable between the ETR and placebo groups.

Neuropsychiatric events have been associated with other NNRTIs. The next-generation NNRTI etravirine (ETR; TMC125) provided durable and statistically superior efficacy versus placebo over 48 weeks in treatment-experienced patients in the Phase III DUET trials. This preplanned, pooled analysis of DUET-1 and DUET-2 focuses on a comparison of nervous system events of interest and psychiatric events observed with ETR versus placebo after patients had received at least 48 weeks of treatment or discontinued.
Patients with documented NNRTI resistance and 3 primary protease inhibitor (PI) mutations received ETR 200mg or placebo, both bid, with a background regimen (BR) of darunavir/with low-dose ritonavir (DRV/r), investigator-selected NRTI(s) ± enfuvirtide (ENF). Specific events were identified by a physician blinded to treatment assignment, prior to database lock, based on the type of events commonly reported with NNRTIs, specifically efavirenz.
The intent-to-treat population included 1203 patients; 599 vs 604 patients received ETR versus placebo, respectively (median age 45 years, 10.7% female, median baseline viral load 4.8 log10 copies/mL, median CD4 cell count 105 cells/mm3).
Incidences of nervous system (17.2% vs 19.7%, p=0.2660) and psychiatric disorders (16.7% vs 19.5%, p=0.2042) with ETR were comparable to placebo.
The most frequent nervous system events were headache (10.9% ETR vs 12.7% placebo), dizziness (3.2% vs 4.3%) and somnolence (1.8% vs 2.3%). The most frequent psychiatric events were insomnia (7.2% vs 8.3%), depression (4.2% vs 6.6%), anxiety (3.8% vs 4.1%) and sleep disorder (1.3% vs 0.8%).
All other events were reported in <1% of patients. Incidences of grade 3 nervous system (0.2% vs 0.8%) and psychiatric (0.3% vs 1.3%) events were low; there were no grade 4 nervous system or psychiatric events in the ETR group.
Nervous system and psychiatric events leading to discontinuation were 0% vs 0.5% and 0.2% vs 0.2%, respectively.
The incidence and severity of neuropsychiatric events observed with ETR was similar to placebo over 48 weeks in the DUET trials.